CurrentCignaPolicy IP0295

Sapropterin products (Javygtor, Kuvan, and generic sapropterin) for phenylketonuria (PKU) — Coverage Criteria

This policy governs medical necessity criteria, authorization, reauthorization, and coverage limitations for sapropterin products (Javygtor, Kuvan, and generic sapropterin) used to treat phenylketonuria (PKU) for members of Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicySapropterin products for PKU — Coverage Criteria

Policy CodePolicy IP0295

Change TypeMaterial clinical revisions and step-therapy additions

Effective Date

Next Review Date

Key ActionObtain prior authorization and document PKU diagnosis (Phe >120 μmol/L or biallelic PAH variants), trial of preferred product per plan, and prescribe or consult with a metabolic disease specialist.

SourceLink

POLICY UPDATE CHANGES

Removed criterion 'No concomitant use with Palynziq once stabilized on Kuvan.'

Reauthorization criterion added: 'Patient has had a clinical response (e.g., cognitive and/or behavioral improvements) as determined by the prescriber.'

Reauthorization criterion updated to require 'increase in dietary phenylalanine tolerance, according to the prescriber' (language changed from earlier phrasing that included neuropsychiatric symptom improvement).

Clarified concomitant therapy language to: 'Patient is not receiving concomitant Palynziq (pegvaliase-pqpz subcutaneous injection) at a stable maintenance dose.'

Preferred product step requirements added for Kuvan and Javygtor (tablets and powder) for Individual and Family Plans.

120diagnostic Phe threshold

120-600reauthorization range (μmol/L)

≥20%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Sapropterin Products

Initial Therapy — Covered when ALL of the following are met for PKU.

Covered when ALL of the following are met for PKU:

Initial PKU Criteria: Member has phenylketonuria (PKU) confirmed by ONE of: (i) plasma phenylalanine concentration persistently above 120 μmol/L with altered Phe:Tyr ratio and normal BH4 cofactor metabolism; OR (ii) finding of biallelic pathogenic or likely pathogenic variants in the PAH gene.

Dietary requirement: Sapropterin is prescribed in conjunction with a phenylalanine-restricted diet.

Prescriber requirement: Medication is prescribed by, or in consultation with, a metabolic disease specialist (or specialist who focuses on the treatment of metabolic diseases).

Preferred product criteria for the products as listed in the policy (see step therapy/preferred product tables) are met.

Reauthorization/Continuation Therapy

Reauthorization covered when ALL of the following are met:

Initial criteria maintained: Above initial medical necessity criteria continue to be met.

Clinical benefit (one of): ONE of the following: (A) Patient has had a clinical response as determined by the prescriber (e.g., cognitive and/or behavioral improvements); OR (B) blood phenylalanine levels are being maintained within an acceptable range (120-600 μmol/L); OR (C) the individual has achieved a greater than or equal to 20% reduction in blood phenylalanine concentration from pre-treatment baseline; OR (D) treatment has resulted in an increase in dietary phenylalanine tolerance according to the prescriber.

Concomitant therapy restriction: Patient is not receiving concomitant therapy with Palynziq (pegvaliase-pqpz subcutaneous injection) at a stable maintenance dose.

Any use of sapropterin products outside the specified indications for tetrahydrobiopterin-responsive phenylketonuria (PKU) is considered experimental, investigational, or unproven and is not covered under this policy.

Laboratory and Diagnostic Thresholds

Phenylalanine levels — Diagnostic and reauthorization targets

Diagnostic thresholdPlasma phenylalanine concentration persistently above 120 μmol/L (2 mg/dL)

Reauthorization/acceptable maintenance range (general)Maintain blood phenylalanine within 120–600 μmol/L

Pediatric target (≤12 years) while treatedTarget phenylalanine levels 120–360 μmol/L

Adult target (≥12 years) while treatedTarget phenylalanine levels 120–600 μmol/L

Required treatment response for continuation>=20% reduction from pre-treatment baseline OR maintained 120–600 μmol/L OR clinical response or increased dietary Phe tolerance as determined by prescriber

Provider Actions, Prior Auth, and Documentation

Prior Authorization

Prior authorization required; approvals up to 12 months

Prior authorization is required for sapropterin products. Initial approvals and reauthorization approvals are each granted for up to 12 months.

Step Therapy

Preferred product step requirements by plan

Preferred product step edits apply and vary by plan type; a trial of the bioequivalent generic or alternative branded formulation is required unless the prescriber documents inability to take the generic due to inactive-ingredient differences causing a significant allergy or serious adverse reaction.

Employer Plans: trial of bioequivalent generic tablets or powder (or Javygtor) required unless documented intolerance to inactive ingredients (chunk 4).
Individual and Family Plans: trial of bioequivalent generic or alternative branded formulation required unless documented intolerance to inactive ingredients (chunk 5).

Covered Indications

Member Eligibility Requirements

Coverage of sapropterin products requires that the member meet the medical necessity criteria for phenylketonuria (PKU) as outlined in this policy, including diagnostic confirmation and concurrent dietary management.

Prior authorization is required for initiation and continuation; initial and reauthorization approvals are available for up to 12 months. Providers must follow preferred product step requirements per plan type and document any medically necessary exceptions.

Background

Sapropterin is a synthetic form of the cofactor for the enzyme phenylalanine hydroxylase and is indicated to reduce blood phenylalanine levels in patients one month of age and older with tetrahydrobiopterin-responsive PKU. It is intended for use in conjunction with a phenylalanine-restricted diet.

Biochemical responsiveness to sapropterin varies; response cannot generally be predicted by laboratory testing and should be determined through a therapeutic trial (evaluation) of sapropterin response.

Definitions and Diagnostic Criteria

PKU — Definition and related notes

DefinitionPhenylketonuria (PKU): a hyperphenylalaninemia due to tetrahydrobiopterin‑responsive phenylketonuria; sapropterin is indicated to reduce blood phenylalanine in these patients.

Age indication per prescribing informationPatients one month of age and older

Treatment contextSapropterin is used in conjunction with a phenylalanine‑restricted diet; biochemical responsiveness varies and is determined by therapeutic trial.

Genetic confirmationPKU may be confirmed by finding biallelic pathogenic or likely pathogenic variants in the PAH gene (supports diagnosis).

Diagnostic criteria for PKU — Confirmation parameters

Biochemical confirmationPersistently elevated plasma phenylalanine >120 μmol/L with altered Phe:Tyr ratio in the untreated state and normal BH4 cofactor metabolism

Not Covered

Use of sapropterin products for indications other than treatment of tetrahydrobiopterin-responsive PKU is not covered and will be considered experimental, investigational, or unproven.